Cargando…

“ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India

BACKGROUND: To improve the public health and promote instant adverse drug reaction (ADR) reporting, a need to develop an ADR Pharmacovigilance Programme of India (PvPI) mobile app was identified by the National Coordination CentrePvPI (NCCPvPI) to serve the Pan India ADR reporting. The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales: Prakash, Jai, Joshi, Kalpana, Malik, Deepak, Mishra, Omkar, Sachan, Akhilesh, Kumar, Bharat, Bhushan, Shashi, Kalaiselvan, Vivekanandan, Singh, Gyanendra Nath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759532/
https://www.ncbi.nlm.nih.gov/pubmed/31571709
http://dx.doi.org/10.4103/ijp.IJP_595_18
_version_ 1783453709778288640
author Prakash, Jai
Joshi, Kalpana
Malik, Deepak
Mishra, Omkar
Sachan, Akhilesh
Kumar, Bharat
Bhushan, Shashi
Kalaiselvan, Vivekanandan
Singh, Gyanendra Nath
author_facet Prakash, Jai
Joshi, Kalpana
Malik, Deepak
Mishra, Omkar
Sachan, Akhilesh
Kumar, Bharat
Bhushan, Shashi
Kalaiselvan, Vivekanandan
Singh, Gyanendra Nath
author_sort Prakash, Jai
collection PubMed
description BACKGROUND: To improve the public health and promote instant adverse drug reaction (ADR) reporting, a need to develop an ADR Pharmacovigilance Programme of India (PvPI) mobile app was identified by the National Coordination CentrePvPI (NCCPvPI) to serve the Pan India ADR reporting. The objective of this study was to develop an indigenous Googlebased Android mobile application known as “ADR PvPI” and to analyze the ADRrelated data reported through this mobile application on pilot basis. MATERIALS AND METHODS: The ADR PvPI mobile application was indigenously developed by NCCPvPI officials within 6 months. The study of spontaneous ADR reporting was carried out between September 2017 and September 2018. This article provides an overview of the salient features of ADR PvPI mobile application, guides on how to fillin ADRs, reporting trends of ADR, types of ADR as per System Organ Class and pharmacological classes of drugs. RESULTS: Till date, >5500 users have downloaded the app with an average rating of 4.26. In that tenure, 262 reports have been received through ADR PvPI mobile app. During the year 2017, 3.55% of reports were received through ADR PvPI mobile app and the percentage of reports received by 2018 was 96.45%. CONCLUSION: The frequency of ADR reporting has significantly increased over the past 1 year and should be promoted further through awareness and training programs.
format Online
Article
Text
id pubmed-6759532
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-67595322019-09-30 “ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India Prakash, Jai Joshi, Kalpana Malik, Deepak Mishra, Omkar Sachan, Akhilesh Kumar, Bharat Bhushan, Shashi Kalaiselvan, Vivekanandan Singh, Gyanendra Nath Indian J Pharmacol Educational Forum BACKGROUND: To improve the public health and promote instant adverse drug reaction (ADR) reporting, a need to develop an ADR Pharmacovigilance Programme of India (PvPI) mobile app was identified by the National Coordination CentrePvPI (NCCPvPI) to serve the Pan India ADR reporting. The objective of this study was to develop an indigenous Googlebased Android mobile application known as “ADR PvPI” and to analyze the ADRrelated data reported through this mobile application on pilot basis. MATERIALS AND METHODS: The ADR PvPI mobile application was indigenously developed by NCCPvPI officials within 6 months. The study of spontaneous ADR reporting was carried out between September 2017 and September 2018. This article provides an overview of the salient features of ADR PvPI mobile application, guides on how to fillin ADRs, reporting trends of ADR, types of ADR as per System Organ Class and pharmacological classes of drugs. RESULTS: Till date, >5500 users have downloaded the app with an average rating of 4.26. In that tenure, 262 reports have been received through ADR PvPI mobile app. During the year 2017, 3.55% of reports were received through ADR PvPI mobile app and the percentage of reports received by 2018 was 96.45%. CONCLUSION: The frequency of ADR reporting has significantly increased over the past 1 year and should be promoted further through awareness and training programs. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6759532/ /pubmed/31571709 http://dx.doi.org/10.4103/ijp.IJP_595_18 Text en Copyright: © 2019 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Educational Forum
Prakash, Jai
Joshi, Kalpana
Malik, Deepak
Mishra, Omkar
Sachan, Akhilesh
Kumar, Bharat
Bhushan, Shashi
Kalaiselvan, Vivekanandan
Singh, Gyanendra Nath
“ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India
title “ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India
title_full “ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India
title_fullStr “ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India
title_full_unstemmed “ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India
title_short “ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India
title_sort “adr pvpi” android mobile app: report adverse drug reaction at any time anywhere in india
topic Educational Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759532/
https://www.ncbi.nlm.nih.gov/pubmed/31571709
http://dx.doi.org/10.4103/ijp.IJP_595_18
work_keys_str_mv AT prakashjai adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia
AT joshikalpana adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia
AT malikdeepak adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia
AT mishraomkar adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia
AT sachanakhilesh adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia
AT kumarbharat adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia
AT bhushanshashi adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia
AT kalaiselvanvivekanandan adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia
AT singhgyanendranath adrpvpiandroidmobileappreportadversedrugreactionatanytimeanywhereinindia